Product Description
for the treatment of DMD in non-ambulatory patients; In multiple preclinical models, Carmeseal-MD, also known as Poloxamer-188 NF or P-188 NF, has been shown to seal the tears that characterize cellular membranes in Duchenne muscular dystrophy. Sealing of these tears leads to improved performance and prolonged survival of these cells, which translates into improved function of the heart, the diaphragm and skeletal limb muscle. (Sourced from: http://phrixuspharmaceuticals.com)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Phrixus Pharmaceuticals
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Muscular Dystrophy, Duchenne
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| P-004 | P2 |
Terminated |
Muscular Dystrophy, Duchenne |
2021-09-01 |
9% |
2023-01-12 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |